GAVI said its that the Independent Assessment Committee of the Advance Market Commitment (AMC) for pneumococcal disease has approved Pfizer’s pneumococcal vaccine Prevenar 13, as eligible for purchase pursuant to the AMC terms and conditions. GAVI said the Pfizer vaccine is the second pneumococcal vaccine to be approved by the committee and that it could be delivered to the GAVI eligible countries as early as this year. UNICEF is the procurement agency for the AMC and will work with countries to determine the introduction dates. In March 2010, Pfizer committed to supply as many as 300 million doses of its vaccine to GAVI countries by 2023.  GAVI noted that “seventy percent of the AMC funds remain available to incentivise additional manufacturers to develop and manufacture pneumococcal vaccines. Therefore, other companies can still make offers under the AMC as new calls for supply offers are issued. Panacea Biotec Ltd, and the Serum Institute of India Ltd. have already registered to the programme and other companies have expressed interest.” In 2007, WHO recommended the introduction of pneumococcal vaccines into all national immunisation programmes, particularly in countries with high child mortality.

http://www.gavialliance.org/media_centre/press_releases/pfizer_amc_approval.php